Caris Life Sciences, Inc. (CAI) Down 5.2% — Is This Where I Say Goodbye?
Caris Life Sciences, Inc. (CAI) is giving back ground this Friday, last trading at $34.26 on the NASDAQ. That is a $1.88 decline from the prior close of $36.14. The pullback comes just two sessions after the stock set its 52-week high of $36.50 on October 28, 2026, and leaves shares about 6.1% below that peak. The stock is still trading near the top of its range, but the reversal from a fresh high shows how quickly recent gains can come under pressure.
Volume is running at roughly 1.07 million shares with the session still open. The 90-day average is about 4.51 million shares, so turnover so far is less than a quarter of a typical full day.
Why Caris Life Sciences, Inc. Price is Moving Lower
The most likely explanation for today's decline is profit-taking after a run to a fresh high, made worse by a risk-off tone across the broader market. Technology sentiment weakened sharply on Friday after Amazon (AMZN) missed Q3 earnings and revenue estimates and Intel (INTC) issued a weaker-than-expected outlook. Nasdaq-100 futures were down 2.5% in premarket trading. That pressure followed a soft Thursday session in which the Nasdaq fell 1.4% and the S&P 500 slipped 0.3%. In that kind of environment, a growth-oriented stock that had just reached $36.50 is an obvious place for investors to lock in gains.
This is not a broad Health Care selloff. The Health Care Sector ETF (XLV) rose 2.4% in the prior session, and peer performance today is mixed. Natera, Inc. (NTRA) is down 2.89% and IQVIA Holdings Inc. (IQV) is off 2.11%, while Zoetis Inc. (ZTS) is up 1.84%. CAI's 5.2% drop is steeper than any of those moves, which points to stock-specific selling rather than a sector-wide retreat.
Upcoming earnings add to that caution. Caris is scheduled to report results on November 4. Consensus calls for EPS of $0.03, down 62.5% year over year, on revenue of $250.9 million, up 15.7%. The bar follows a strong prior quarter. In the report released on August 5, Caris posted break-even adjusted EPS against an expected $0.01 loss and a $0.54 loss a year earlier. Revenue of $263.71 million topped consensus by 14.07% and rose 45% year over year. Net loss narrowed to $0.637 million from $71.79 million, and management raised 2026 revenue guidance to $1.03 billion to $1.04 billion. After a quarter that strong and a rally to new highs, investors appear less willing to hold through another report while the wider market is turning defensive.
What is the Caris Life Sciences, Inc. Rating - Should I Sell?
Weiss Ratings assigns CAI a D rating. Current recommendation is Sell. The rating balances genuine operating progress against a stock profile that remains risky for investors. Caris is growing quickly and has started to report profits, but its valuation and price behavior have not yet given holders a dependable risk/reward balance.
The clearest strength is the balance sheet. Caris is rated Excellent on the Solvency Index, which suggests the company can fund its sequencing, data, and commercial expansion without heavy financial strain. That matters for a business that only recently moved toward break-even. The Fair rating on the Efficiency Index tells a more measured story. A 20.13% ROE and a 10.62% profit margin show the business can now convert revenue into returns. However, last quarter still ended in a small net loss of $0.637 million, so that profitability is too new to support a higher rating.
The weaker dimensions explain why the overall rating sits at D. The Weak rating on the Growth Index may look surprising next to 45.38% revenue growth. The gap is in earnings, not sales: consensus expects quarterly EPS of $0.03, a 62.5% year-over-year decline. A forward P/E of 102.00 also assumes growth that has yet to show up consistently on the bottom line. The Total Return Index and Volatility Index are both rated Weak. Today's 5.2% slide, two days after a 52-week high and driven by profit-taking in a risk-off market, shows how sharply this stock can swing on sentiment alone.
Within the Health Care sector, Caris ranks ahead of Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+). That is a narrow edge in a peer group where every name carries a Sell recommendation.
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (CAI) is a Health Care company focused on precision oncology. Based in Irving, Texas, Caris uses comprehensive molecular profiling and artificial intelligence to help oncologists match cancer patients with targeted therapies. Its main tissue-based offering, MI Profile, combines whole exome and whole transcriptome sequencing with protein analysis to characterize a patient's tumor in depth. MI Cancer Seek extends that approach as a companion diagnostic for therapy selection.
The company has expanded beyond tissue testing with Caris Assure, a blood-based liquid biopsy platform. Caris Assure is designed to support therapy selection and minimal residual disease monitoring and is being studied for earlier cancer detection. This breadth lets Caris serve patients at several points in their treatment rather than only at diagnosis, and it supports the testing volume behind the company's recent revenue acceleration.
Caris's main competitive advantage is its large clinico-genomic database, which links molecular profiles with real-world treatment outcomes. The company monetizes that data through partnerships with biopharmaceutical companies seeking help with drug discovery, clinical trial design, and patient identification. It also convenes the Caris Precision Oncology Alliance, a network of cancer centers and academic institutions that collaborate on research. This combination of scale in sequencing, depth of data, and institutional relationships is difficult for smaller diagnostics competitors to replicate. Even so, Caris operates in a field shaped by reimbursement decisions, regulatory oversight, and rapid technological change.
Investor Outlook
Caris Life Sciences, Inc. (CAI) carries a Weiss Rating of D (Sell). Strong top-line growth and an excellent balance sheet are offset by a demanding valuation and volatile trading. The November 4 report is the key near-term test: investors should watch whether results clear the $0.03 EPS estimate and whether management reaffirms or raises its $1.03 billion to $1.04 billion revenue guidance. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--